INTRODUCTION
============

Protein homeostasis is influenced by the synthesis, folding, trafficking, and degradation of proteins ([@B30]; [@B33]). Cells recognize disruption of protein homeostasis and induce regulatory networks that remediate loss of proteostatic control. The unfolded protein response (UPR) is an important example of a regulatory network that responds to disruptions in protein homeostasis in the endoplasmic reticulum (ER; [@B41]). Perturbations in calcium homeostasis, redox status, and protein turnover can disrupt the ER, leading to accumulation of misfolded proteins that activate the UPR, consisting of translational and transcriptional control networks that serve to expand the protein-processing capacity of the ER ([@B35]; [@B41]). Central to the UPR is an ER transmembrane protein kinase, PERK (EIF2AK3/PEK), which is believed to sense accumulating misfolded proteins in the ER lumen, triggering repression of protein synthesis by phosphorylation of the α subunit of eIF2 ([@B45]; [@B2]; [@B41]). Translational control limits influx of newly synthesized proteins into the ER, preventing further ER overload. Phosphorylation of eIF2α (eIF2α∼P) is not unique to ER stress, as activation of three other eIF2α kinases, GCN2 (EIF2AK4), HRI (EIF2AK1), and PKR (EIF2AK2), occurs in response to diverse stress conditions that can affect protein homeostasis in the cytoplasm ([@B4]; [@B45]; [@B2]). In a sense these translational changes are believed to act as a "shut-off valve," which would prevent further organelle stress and cellular damage ([@B45]; [@B28]).

Coincident with dampening of global translation, eIF2α∼P leads to preferential translation of select mRNAs, such as that encoding ATF4 ([@B10]; [@B40]). ATF4 is a basic zipper (bZIP) transcription activator of genes involved in protein folding and assembly, metabolism and nutrient uptake, and antioxidation, which together can serve to remedy stress damage ([@B11]). The eIF2α∼P/ATF4 pathway has been termed the integrated stress response (ISR) because diverse stress conditions that elicit eIF2α∼P converge on a common target, ATF4 ([@B11]). The ISR shares core features with eIF2α∼P and the general amino acid control pathway in budding yeast ([@B12]). In mammalian cells, however, eIF2α∼P leads to preferential translation of a collection of different genes. In addition to ATF4, eIF2α∼P enhances the translation of *CHOP* (*GADD153*/*DDIT3*) and *ATF5* that encode bZIP transcription factors and ultimately a protein phosphatase 1c--targeting subunit encoded by *GADD34* (*PPP1R15A*), which facilitates feedback dephosphorylation of eIF2α∼P ([@B43]; [@B49]; [@B16]; [@B26]; [@B41]). There are two alternatively spliced *ATF5* transcripts, with *ATF5*α being the predominant version, which is expressed postnatally and is subject to enhanced translation in response to eIF2α∼P ([@B9]; [@B43]; [@B49]).

Although the ISR is critical for alleviating damage accrued during acute stress, the eIF2α∼P response can instead switch to a terminal outcome during periods of extended environmental challenge ([@B37]). This dual nature of the ISR during endoplasmic reticulum stress has been referred to as a "binary switch" ([@B25]). Among ISR genes, *CHOP* is considered a precipitator of stress-induced apoptosis. The underlying mechanisms by which the eIF2∼P/ATF4/CHOP pathway can signal cell death are not well understood. It is suggested that chronic stress leads to protracted and elevated levels of CHOP protein, which can achieve a threshold of activity invoking a network of gene expression favoring apoptosis ([@B34]; [@B37]). CHOP is suggested to facilitate cell death through regulation of genes that are central for the control of apoptosis. For example, CHOP is suggested to repress the transcriptional expression of the prosurvival gene *BCL2* ([@B22]). BCL2 can enhance survival by sequestration of BH3-only proteins, including BIM and PUMA, which are important for BAX-BAK--mediated permeabilization of the mitochondrial membrane, facilitating subsequent release of cytochrome C and apoptosis ([@B47]). Furthermore, CHOP has been reported to tilt the balance between these BCL2 member proteins toward apoptosis by directly enhancing *BIM* expression ([@B31]). Other mechanisms by which CHOP is suggested to trigger apoptosis are by inducing expression of *GADD34*, which can prematurely enhance protein synthesis during chronic stresses, and increasing ERO1α levels, which can induce cytotoxic reactive oxygen species during prolonged ER stress ([@B23]; [@B11]; [@B21]).

The focus of this study is on the mechanisms by which CHOP and the ISR can control cell survival in response to alterations in protein homeostasis. Of particular interest are transcriptome changes directed by CHOP in response to disruptions in protein degradation, a potent inducer of eIF2α∼P and the ISR, and how these gene expression changes can affect cell survival. We find that CHOP can induce expression of genes favoring remediation of stress damage, as well as those signaling apoptosis. Of interest, central to the changes in the transcriptome directed by CHOP is the finding that CHOP enhances the expression of many additional transcription factors that comprise additional "nodes" of a transcription network that reinforce and amplify stress responses. Included among these CHOP-targeted transcription factors is ATF5, which we show is a direct downstream target of CHOP and ATF4. ATF5 serves to potentiate CHOP-dependent apoptosis in response to inhibition of proteasome inhibition and other disruptions of protein homeostasis. This study places CHOP upstream of a network of transcriptional regulators in the ISR pathway and identifies new target genes of ATF5 that mediate the apoptotic response to stress.

RESULTS
=======

CHOP is required for expression of additional transcriptional regulators in the ISR
-----------------------------------------------------------------------------------

Elevated and sustained levels of CHOP protein are suggested to adversely affect cell fates in response to disruptions in protein homeostasis. With this in mind, we measured changes in the transcriptome by microarray analysis in wild-type (WT) and *CHOP*^−/−^ mouse embryonic fibroblast (MEF) cells upon treatment with 1 μM MG132 for 8 h. MG132 is a proteasome inhibitor and potent pharmacological inducer of eIF2α∼P and *CHOP* expression ([@B13]). In response to MG132 treatment, 8321 genes as defined by probe sets were significantly changed ([Table 1](#T1){ref-type="table"}). Among these genes, 3316 (39.8%) were found to be *CHOP* dependent, with 1520 genes enhanced (42%) and 1796 genes lowered (38%) in response to proteasome inhibition. These findings are also illustrated in [Figure 1A](#F1){ref-type="fig"}, which features a scatter-plot analysis of stress-induced transcriptome changes in WT cells (*x* axis) versus *CHOP*^−/−^ cells (*y*-axis). The *CHOP* requirement for changes in the transcriptome is supported by the large number of probe sets that were increased in the WT cells on stress but induced to a lesser extent in *CHOP^−/-^* cells.

![Genome-wide analysis of CHOP-dependent genes regulated by proteasome inhibition. (A) The scatter plot is the log ratio of WT (*x*-axis) and *CHOP*^−/−^ MEF cells (*y*-axis) treated with 1 μM MG132 for 8 h versus no stress. This comparative analysis of gene transcripts illustrates all significant probe sets (*p* \< 0.05) induced or repressed upon MG132 treatment. (B) Pie charts generated by IPA analysis, which highlight functional classes of *CHOP*-dependent genes. (C) IPA comparison of *CHOP*-dependent genes classified by role in cells.](2477fig1){#F1}

###### 

Genes regulated by CHOP in response to treatment with MG132.

                                                 Fold change (treated/untreated)^a^                              
  -------------------------- ------------------- ------------------------------------ ------------ ------------- ------------
  Total MG132                8321^b^             3607                                 695          4714          966
  CHOP-dependent MG132 (%)   3316^c^ (39.8)^d^   1520 (42.1)                          332 (47.7)   1796 (38.1)   350 (36.2)

^a^Expression profile summary of gene transcripts, as defined by probe sets, that were significantly changed (*p* ≤ 0.05) after treatment with 1 μM MG132 for 8 h. The number of induced genes is shown for both \>1.0-fold and ≥2.0-fold thresholds. The repressed genes are also shown for \<1.0- and ≤0.5-fold thresholds.

^b^Transcripts significantly changed (*p* ≤ 0.05) by proteasome inhibition.

^c^The number of CHOP-dependent transcripts that were significantly changed by proteasome inhibition.

^d^Numbers in parentheses are the percentage of CHOP-dependent genes compared with the total gene expression changed in response to MG132 treatment.

Pathway analysis of the *CHOP*-dependent genes was performed using Ingenuity Pathway Analysis (IPA) software to group the target genes into functional categories. The top functional groups are depicted in [Figure 1B](#F1){ref-type="fig"}, where CHOP-dependent gene networks are found to be associated with a range of molecular and cellular functions in the categories of cell death, cellular growth and proliferation, cell cycle, and cellular assembly, organization, and maintenance. These results suggest that although CHOP-targeted genes participate in cell death, they can also play a role in a diverse set of cellular functions ([Figure 1C](#F1){ref-type="fig"}). CHOP-dependent genes include *HSPA1A* and *DNAJA4* involved in protein folding, *NOXA*, *APAF1*, and *GAS5* involved in cell death, and 223 genes involved in regulation of transcription, including *MLF1*, *ATF7IP2*, and *ATF5.* This collection of transcription factors is highlighted in [Table 2](#T2){ref-type="table"}, and an expanded list of all 223 genes is provided in Supplemental Table S1.

###### 

Functional classes of genes requiring CHOP for full induction in response to proteasome inhibition.

  Probe ID^a^                  Gene name                                                     Gene symbol   Fold-NT (WT/KO)^b^   Fold-MG132 (WT/KO)^c^
  ---------------------------- ------------------------------------------------------------- ------------- -------------------- -----------------------
  **Transcription factor**                                                                                                      
  1417516_at                   C/EBP-homologous protein                                      CHOP          2.8                  19.5
  1416967_at                   SRY-box--containing gene 2                                    SOX2          9.6                  13.9
  1418271_at                   Basic helix-loop-helix family, member e22                     BHLHE22       2.8                  6.6
  1440275_at                   Runt-related transcription factor 3                           RUNX3         7.7                  4.4
  1421469_a\_at                Signal transducer and acti­vator of transcription 5A          STAT5A        3.1                  3.4
  1416981_at                   Forkhead box O1                                               FOXO1         3.7                  2.9
  1427938_at                   c-Myc--binding protein                                        MYCBP         1.4                  2.2
  1425927_a\_at                Activating transcription factor 5                             ATF5          3.6                  1.8
  1418589_a\_at                Myeloid leukemia factor 1                                     MLF1          2.1                  2.5
  1427603_at                   Activating transcription factor 7 interacting protein 2       ATF7IP2       2.2                  6.4
  **Translation initiation**                                                                                                    
  1435904_at                   Eukaryotic translation initiation factor 2C, 3                EIF2C3        1.9                  1.9
  **Apoptosis**                                                                                                                 
  1418203_at                   Phorbol-12-myristate-13-acetate--induced protein 1            NOXA          2.5                  3.3
  1436222_at                   Growth arrest specific 5                                      GAS5          2.8                  2.1
  1435448_at                   BCL2-like 11 (apoptosis facilitator)                          BIM           0.7                  1.3
  **Phosphatase activity**                                                                                                      
  1429514_at                   Phosphatidic acid phosphatase type 2B                         PPAP2B        33.7                 21.6
  1415834_at                   Dual-specificity phosphatase 6                                DUSP6         0.5                  2.3
  1448325_at                   Myeloid differentiation primary response gene 116             GADD34        1.6                  1.4
  1455728_at                   Phosphatase and tensin homologue                              PTEN          1.9                  1.2
  **Protein folding**                                                                                                           
  1419625_at                   Heat shock protein 1A                                         HSPA1A        2.7                  3.0
  1434196_at                   DnaJ (Hsp40) homologue, subfamily A, member 4                 DNAJA4        1.1                  2.7
  1426260_a\_at                UDP glycosyltransferase 1 family, polypeptide A6              UGT1A6        4.2                  7.2
  1455346_at                   Mannan-binding lectin serine peptidase 1                      MASP1         3.3                  3.7
  **Cytokine signaling**                                                                                                        
  1451798_at                   Interleukin 1 receptor antagonist                             IL1RN         9.0                  12.8
  1417625_s\_at                Chemokine (C-X-C motif) receptor 7                            CXCR7         1.9                  5.6
  1436861_at                   Interleukin 7                                                 IL7           1.7                  2.1
  **Miscellaneous**                                                                                                             
  1421001_a\_at                Carbonic anhydrase 6                                          CAR6          2.7                  24.9
  1436555_at                   Solute carrier family 7, member 2                             SLC7A2        3.3                  4.5
  1434714_at                   ERO1-like β (*Saccharomyces cerevisiae*)                      ERO1LB        1.7                  2.4
  1424048_a\_at                Cytochrome b5 reductase 1                                     CYB5R1        1.1                  1.8
  1418599_at                   Collagen, type XI, alpha 1                                    COL11A1       5.9                  3.9
  1417421_at                   S100 calcium-binding protein A1                               S100A1        4.1                  3.6
  1443250_at                   Regulator of G protein signaling 2                            RGS2          1.0                  1.9
  **Fatty acid synthesis**                                                                                                      
  1439478_at                   Acyl-CoA thioesterase 2                                       ACOT2         2.1                  11.5
  1424097_at                   ELOVL family member 7, elongation of long-chain fatty acids   ELOVL7        8.7                  7.8

^a^Affymetrix Mouse 430 2.0 array, probe set identifier.

^b^Mean fluorescence intensity fold difference between WT and *CHOP*^−/−^ cells, no treatment (NT).

^c^Mean fluorescence intensity fold difference between WT and *CHOP*^−/−^ cells, MG132 (8 h).

*ATF5* was among the *CHOP*-dependent genes, and based on microarray data, the *ATF5* transcript was 3.6-fold higher in the WT cells under basal conditions and 1.8-fold in stressed conditions when compared with *CHOP^−/−^* cells ([Table 2](#T2){ref-type="table"}). These results suggest that CHOP is required for *ATF5* mRNA synthesis in both basal and stressed conditions. We previously reported that *ATF5* was subject to preferential translation in response to eIF2α∼P ([@B49]), and we elected to characterize the transcriptional activation and biological significance of *ATF5* as a new CHOP target gene.

CHOP is required for transcriptional expression of *ATF5* and binds to CARE elements in the *ATF5* promoter
-----------------------------------------------------------------------------------------------------------

The importance of CHOP for induced *ATF5* mRNA in the ISR was further analyzed by using quantitative PCR (qPCR) and RNA prepared from the WT and *CHOP^−/−^* cells. In response to treatment with MG132, there was a 1.5-fold increase in *ATF5* mRNA levels in WT cells, whereas in *CHOP*^−/−^ cells the amount of *ATF5* transcript was reduced ∼50% upon proteasome inhibition ([Figure 2A](#F2){ref-type="fig"}). The CHOP requirement for increased *ATF5* mRNA was also seen when these MEF cells were treated with thapsigargin, which elicits ER stress and eIF2α∼P due to calcium disruption in this organelle ([Figure 2B](#F2){ref-type="fig"}). In WT cells, there was a fourfold in increase in *ATF5* mRNA, which was significantly lowered in *CHOP*^−/−^ cells. As expected, *CHOP* mRNA levels were dramatically increased in WT cells during either stress arrangement, and there were no detectable *CHOP* transcripts in the *CHOP*^−/−^ cells ([Figure 2, A and B](#F2){ref-type="fig"}). In further controls, we found that CHOP was required for full induction of *GADD34* mRNA and repression of the prosurvival *BCL2* gene during the ISR ([Figure 2A](#F2){ref-type="fig"}), consistent with earlier reports ([@B22]; [@B21]). Supporting the idea that ATF4 is an upstream activator of *CHOP* transcription in the ISR, the amount of *ATF4* mRNA was enhanced in either WT or *CHOP*^−/−^ cells exposed to MG132 or thapsigargin. In fact, the *ATF4* transcripts were further elevated in the stressed *CHOP*-deficient cells ([Figure 2, A and B](#F2){ref-type="fig"}), suggesting that there is an extended ISR response with loss of expression of *CHOP* and its downstream target gene *GADD34*, which is required for feedback control of the ISR. Together these results indicate that CHOP is required for increased *ATF5* mRNA in response to different stress conditions that activate the ISR, with the measured dose of the ER stress agent thapsigargin triggering the greatest enhancement of ATF5 mRNA levels compared with MG132 treatment.

![CHOP is required for enhanced *ATF5* mRNA levels. WT or *CHOP*^−/−^ MEF cells were treated with 1 μM MG132 (A) or 1 μM thapsigargin (TG; B) for 8 h, and the levels of *ATF4*, *CHOP*, *ATF5*, and *GADD34* mRNAs were determined by qPCR. \*Statistical significance (*p* \< 0.05) with respect to the untreated control. ^\#^Significant difference (*p* \< 0.05) between cell types. n.d., not detectable.](2477fig2){#F2}

Potential CHOP-binding elements are situated in the *ATF5* promoter from the base pair −2500 to −3000 region relative to the *ATF5* transcriptional start site. These binding sites, termed CARE elements, can be placed in either orientation ([@B27]; [@B15]), and in the *ATF5* promoter these were designated CARE-1 (5′-TGATGGAAA-3′) and CARE-2 (5′-TGATGCAAC-3′; [Figure 3A](#F3){ref-type="fig"}). We therefore carried out chromatin immunoprecipitation (ChIP) analyses to measure ATF4 and CHOP occupancy on the *ATF5* promoter at these CARE sites. Both CHOP and ATF4 were found to associate with DNA including the CARE-2 element (designated P2) in the *ATF5* promoter, with significantly enhanced binding in response to MG132 ([Figure 3B](#F3){ref-type="fig"}) or thapsigargin treatment ([Figure 3C](#F3){ref-type="fig"}). By contrast, there was only modest binding of ATF4 and CHOP to the CARE-1 segment (designated P1), which is predicted to be a suboptimal CHOP-binding site due to a G in position 6 ([@B3]; [@B48]). The third site tested is located in an exon (designated P3) and was used as a negative control. As expected, there was minimal ATF4 or CHOP binding at the P3 site in the presence or absence of the stresses ([Figure 2, B and C](#F2){ref-type="fig"}). Finally, no signal was detected using a nonspecific immunoglobulin G (IgG) in the ChIP assay ([Figure 2B](#F2){ref-type="fig"}). Enhanced binding of ATF4 and CHOP was also found specifically at the P2 site upon treatment with tunicamycin, which elicits ER stress by impairing N-glycosylation in this organelle (Supplemental Figure S1). These results support the idea that both CHOP and ATF4 bind directly to the *ATF5* promoter to facilitate increased transcription in response to diverse stress conditions that elicit the ISR.

![CHOP facilitates transcriptional activation of *ATF5* by binding to CARE elements in the *ATF5* promoter. (A) Diagram of potential CARE sequences present in the *ATF5* promoter region, as determined by in silico analysis. The values −2.5 and −3.0 kb are relative to the transcriptional start site. Cells were treated with MG132 (B), thapsigargin (TG; C), or no treatment (NT), and chromatin immunoprecipitation was performed with antibodies specific for ATF4, CHOP, or nonspecific IgG as a negative control. qPCR was performed, and the enrichment relative to input DNA is shown for each of three genomic regions. The regions amplified by primer sets P1 and P2 include the possible CARE sequences, whereas the primer set designated P3 amplified a region located in exon 3 that does not contain a CARE site and serves as a negative control.](2477fig3){#F3}

CHOP is required for ATF5 protein expression during diverse stress conditions
-----------------------------------------------------------------------------

Because expression of *ATF5* is also regulated at the level of mRNA translation, it was important to determine whether CHOP was required for increased ATF5 protein. WT and *CHOP^−/−^* MEF cells were treated with MG132 for up to 24 h, and the levels of eIF2α∼P and downstream ISR effectors, ATF4 and CHOP proteins, were enhanced early, within 1--3 h of proteasome inhibition ([Figure 4A](#F4){ref-type="fig"}). As expected, no CHOP protein was detected in the *CHOP^−/−^* cells, whereas induction of ATF4 protein and another ISR transcription factor, ATF3, were largely unaffected. ATF5 protein was increased within 3 h of treatment of WT cells with MG132, but there were significantly lowered levels of ATF5 in the *CHOP*^−/−^ cells, with only modest amounts of ATF5 protein after 12 h of proteasome inhibition.

![CHOP is required for *ATF5* protein expression in response to proteasome inhibition. (A) WT and *CHOP*^−/−^ MEF cells were treated with 1 μM MG132 for up to 24 h as indicated. Time 0 indicates no stress treatment. Levels of eIF2α∼P, eIF2α, ATF4, CHOP, ATF3, ATF5, caspase-3 (CASP-3 and the cleaved version), cleaved PARP, and actin were determined by immunoblot analysis using antibody specific to the protein of interest. (B) *CHOP*^−/−^ cells and those stably expressing CHOP from an FRT locus were exposed to 1 μM MG132 for up to 24 h. Levels of CHOP, ATF4, ATF5, and actin proteins were determined by immunoblot analysis. Levels of *ATF5* (C) and *GADD34* (D) mRNAs were measured by qPCR in WT, *CHOP*^−/−^, and rescued *CHOP*^−/−^ cells that were stably expressing *CHOP*. Cells were treated with 1 μM MG132 for up to 12 h or not treated (NT). (E) HEPA1-6 cells stably expressing a control scrambled (Scr) shRNA or a *CHOP*-targeted shRNA were treated with 1 μM MG132 for 8 h. In lanes 3--5, the RNA Consortium (TRC) ID number indicates the last two digits for the validated *CHOP*-targeted shRNA identification number obtained from Sigma-Aldrich. Levels of CHOP, ATF5, and actin proteins were determined by immunoblot analysis. (F) WT and *CHOP*^−/−^ MEF cells were treated for 24 h with 1 μM MG132 or no treatment (NT) and subjected to FACS analyses using annexin V--FITC/PI staining. \*Statistical significance (*p* \< 0.05) compared with the untreated control. ^\#^Significant difference (*p* \< 0.05) between WT and *CHOP*^−/−^ cell types.](2477fig4){#F4}

Stable expression of *CHOP* into the *CHOP*^−/−^ MEF cells significantly enhanced ATF5 protein levels in response to MG132 treatment but did not appreciably alter induced expression of the upstream ATF4 ([Figure 4B](#F4){ref-type="fig"}). Of interest, the rescue of *CHOP* expression in the *CHOP*^−/−^ MEF cells led to elevated levels of *ATF5* mRNA even in the absence of proteasome inhibition ([Figure 4C](#F4){ref-type="fig"}). By contrast, expression of the ISR target gene *GADD34* showed induced transcript levels in the rescued *CHOP*^−/−^ cells in response to MG132 treatment that were comparable to WT cells ([Figure 4D](#F4){ref-type="fig"}). These results support the idea that elevated levels of CHOP can be sufficient for induced *ATF5* mRNA, and the subsequent enhancement of ATF5 protein requires preferential translation triggered by eIF2α∼P. Finally, to address whether CHOP is required for enhanced ATF5 expression in other cell types, we used a lentiviral system and short hairpin RNA (shRNA) to stably knock down *CHOP* expression in mouse liver Hepa1-6 cells subjected to proteasome inhibition. Using stable transfectants derived from three different validated shRNAs, we found that lowered CHOP levels in the Hepa1-6 cells led to reduced expression of ATF5 protein upon treatment with MG132 ([Figure 4E](#F4){ref-type="fig"}).

Given that eIF2α∼P and the ISR are induced by many different stress conditions, we also addressed whether CHOP facilitates increased ATF5 protein in response to treatment with thapsigargin, arsenite, or histidinol (Supplemental Figure S2, A--C). In each stress condition, there was a significant diminishment and delay in the induction of ATF5 protein in the *CHOP*^−/−^ cells as compared with WT. These results support the idea that CHOP is required for full induction of *ATF5* expression in the ISR during different stress conditions and in multiple cell types.

CHOP and ATF5 facilitate apoptosis during proteasome inhibition
---------------------------------------------------------------

CHOP has a potent proapoptotic function in the ISR during extended stress arrangements. This is illustrated by the observation that although cleavage of PARP, a marker of apoptosis, was present in WT cells after 24 h of MG132 exposure, there was minimal detected cleaved PARP in *CHOP*^−/−^ cells ([Figure 4A](#F4){ref-type="fig"}). Furthermore, cleavage of caspase 3 was reduced during this stress regimen upon loss of *CHOP*. Consistent with the idea that CHOP can facilitate cell death in response to cellular stresses, *CHOP*^−/−^ cells showed significantly lower levels of apoptosis during MG132 treatment as compared with WT cells ([Figure 4F](#F4){ref-type="fig"}). Reduced amounts of cleaved caspase 3 and PARP were also seen in the *CHOP*^−/−^ cells upon thapsigargin and arsenite treatments (Supplemental Figure S2, A and B), supporting the notion that CHOP can signal apoptosis during different chronic stresses.

Having established that *ATF5* expression was dependent on CHOP, we next wanted to investigate the role of ATF5 in cell survival during stress. To achieve this goal, we used a lentiviral delivery system and shRNA to stably knock down ATF5 in MEF cells. Using a collection of different shRNAs, we were able to achieve 50--72% knockdown of the *ATF5* transcripts compared with no significant difference in knockdown in the scramble control ([Figure 5A](#F5){ref-type="fig"}). Two cell lines, designated *ATF5*-KD1 and *ATF5*-KD2, with the highest percentage knockdown of *ATF5* mRNA (58 and 72%, respectively) were selected for further characterization. The amount of ATF5 protein in these knockdown cells was also sharply lowered after up to 24 h of MG132 treatment ([Figure 5B](#F5){ref-type="fig"}). Supporting the idea that ATF4 and CHOP proteins are upstream activators of *ATF5* expression, the levels of ATF4 and CHOP upon exposure to MG132 were similar between WT cells and the *ATF5*-knockdown cells ([Figure 5B](#F5){ref-type="fig"})

![ATF5 facilitates apoptosis in response to proteasome inhibition. (A) RNA was isolated from MEF cells stably expressing a scrambled shRNA or an ATF5-targeted shRNA, and *ATF5* mRNA levels were determined by qPCR relative to non-shRNA--expressing control. The ID number indicates the last two digits for the shRNA. The percentages of *ATF5* knockdown were determined relative to a non-shRNA--expressing control. (B) WT, *ATF5*-KD1, and *ATF5*-KD2 MEF cells were treated with MG132 for the indicated time points. Levels of ATF4, CHOP, ATF5, cleaved caspase-9, cleaved caspase-3, cleaved PARP, and actin proteins were measured by immunoblot analysis using specific antibodies. (C) Cell treatment regimen for the data shown in D. Cells were cultured with 1 μM MG132 for 0, 1, 3, 6, 12, or 18 h as indicated by the black bars, and after the stress treatment, cells were cultured in the absence of MG132, as indicated by the gray bars, for a total of 24 h. (D) Measurements of survival of WT, *CHOP*^−/−^, *ATF5*-KD1, and *ATF5*-KD2 MEF cells were determined by the MTT assay, and the percentage of cell survival is normalized to the untreated controls for each cell type.](2477fig5){#F5}

The role of ATF5 in the control of cell survival was addressed by treating WT and the *ATF5* knockdown cells with proteasome inhibitor, followed by the MTT assay to measure cell viability. WT, *CHOP^−/−^*, *ATF5*-KD1, and *ATF5*-KD2 cells were exposed to MG132 for between 1 and 18 h as outlined in [Figure 5C](#F5){ref-type="fig"}. After each stress time point, fresh medium with no drug was added, and cells were allowed to recover from the stress insult for the remainder of the time course (total 24 h). Both the *ATF5*-KD1 and *ATF5*-KD2 cell lines showed enhanced survival at each time point of MG132 exposure compared with WT cells ([Figure 5D](#F5){ref-type="fig"}). The increased survival of the *ATF5*-knockdown cells was similar to that determined for *CHOP^−/−^* cells. Furthermore, there were significantly lowered levels of cleaved caspase 3 and PARP in the *ATF5*-KD1 and *ATF5*-KD2 cells treated with MG132 as compared with WT ([Figure 5B](#F5){ref-type="fig"}). These results support the idea that both CHOP and ATF5 facilitate apoptosis during perturbations in protein homeostasis.

ATF5 is required for activation of proapoptotic target genes in response to proteasome inhibition
-------------------------------------------------------------------------------------------------

To determine the transcriptome changes directed by ATF5 transcription factor and its possible effect on the regulation of apoptosis, we carried out a microarray analysis of WT and *ATF5-KD2* cells treated with MG132 or no stress. A total of 8055 genes as defined by probe sets were significantly changed in response to MG132 treatment ([Table 3](#T3){ref-type="table"}). Among these genes, 3075 (38%) were dependent on ATF5, with 1714 (45%) increased and 1361 (32%) reduced. We again used IPA software to analyze the functional classes of ATF5-dependent genes, which are depicted in [Figure 6A](#F6){ref-type="fig"}. The ATF5-dependent gene network is associated with some different functional classes when compared with the networks characterized for CHOP-dependent genes. Classes of the ATF5-dependent gene network included genes involved in protein synthesis, protein degradation, and gene expression ([Figure 6A](#F6){ref-type="fig"}), as well as those linked with cancers and hematological system development and function. We compared the set of genes requiring ATF5 for full induction with our previous microarray data set of *CHOP*-dependent genes and found 348 genes that were dependent on both CHOP and ATF5 ([Figure 6B](#F6){ref-type="fig"}). Among these genes were those involved in protein folding, including *HSPA1A* and *DNAJA4*, transcriptional regulators *ATF7IP2* and *MLF1*, and proapoptotic genes *GAS5* and *NOXA* ([Figure 6C](#F6){ref-type="fig"}). There were also 1366 genes regulated by ATF5 but independent of CHOP, including *APAF1* and *TXNIP*, involved in apoptosis and the inflammatory response, respectively. Therefore, concerning the roles of ATF5 and CHOP in the ISR-directed transcriptome, there are genes that are ATF5 dependent or CHOP dependent and those requiring both transcription factors for full induction in response to MG132 treatment. We confirmed by qPCR several of the key findings in this microarray data set ([Figure 7A](#F7){ref-type="fig"}). Furthermore, we confirmed by qPCR and immunoblot that *ATF5* mRNA and protein are depleted in the *ATF5*-KD2 cells and the upstream CHOP expression is unaffected ([Figures 5B](#F5){ref-type="fig"} and [7A](#F7){ref-type="fig"}).

![Genome-wide analysis of gene expression indicates that ATF5 is required for activation of proapoptotic target genes. Results from a microarray analysis of WT and *ATF5-KD2* cells treated with MG132 or no stress indicated those genes that significantly required ATF5 for full induction in response to proteasome inhibition. These ATF5-target genes were then analyzed for functional groupings and compared with those genes determined in our microarray analysis to be statistically dependent on CHOP for full induction in response to MG132 treatment. (A) Pie charts generated by IPA analysis, highlighting functional classes of *ATF5*-dependent genes. (B) Venn diagram indicating the number of genes that required only CHOP for full induction response to MG132 treatment, those genes dependent on both CHOP and ATF5, and genes dependent on only ATF5. (C) Comparative bar graph showing that *GADD34* required only CHOP for full induction in response to proteasome inhibition, examples of genes whose induction showed a statistically significant dependence on both CHOP and ATF5, and those genes requiring only ATF5; values represent mean fluorescence intensity (MFI) in WT and *ATF5*-KD2 cells upon MG132 treatment or no treatment (NT).](2477fig6){#F6}

![shRNA knockdown of *NOXA* protects cells from stress induced by MG132 treatment. (A) WT and *ATF5*-KD2 MEF were treated with 1 μM MG132 for 8 h or no treatment (NT). The mRNA levels for *CHOP*, *ATF5*, *NOXA*, *TXNIP*, and *APAF1* were measured by qPCR. In addition, *NOXA* mRNA was measured in *ATF5*-KD1 cells as indicated. \*Statistical significance (*p* \< 0.05) with respect to the untreated control. ^\#^Difference between cell types. (B) MEF cells expressing an shRNA targeting *NOXA* or scramble control were treated for 8 h with MG132. The last two digits in the validated shRNA identification number are listed. Relative *NOXA* mRNA levels were measured by qPCR. \*Statistical significance (*p* \< 0.05). (C) WT, *CHOP*^−/−^, and *NOXA*-KD MEF cells were treated with 1 μM MG132 for 24 h, and cell death was determined as the percentage of viable cells as measured by MTT assay upon MG132 treatment compared with untreated controls. (D) WT and *TXNIP-*KD MEF cells were treated with 1 μM MG132 for 12 h, and the relative level of *TXNIP* mRNA was measured by qPCR. (E) Death of WT and TXNIP-KD cells was measured as the percentage of viable cells as determined by MTT assays after 24 h of MG132 treatment compared with untreated controls.](2477fig7){#F7}

###### 

Genes regulated by ATF5 in response to treatment with proteasome inhibition.

                                                 Fold change (treated/untreated)^a^                             
  -------------------------- ------------------- ------------------------------------ ----------- ------------- -----------
  Total MG132                8055^b^             3833                                 69          4222          72
  ATF5-dependent MG132 (%)   3075^c^ (38.1)^d^   1714 (44.7)                          52 (75.3)   1361 (32.2)   41 (56.9)

^a^Expression profile summary of gene transcripts, as defined by probe sets that were significantly changed (*p* ≤ 0.05) during treatment with 1 μM MG132 for 8 h. The number of induced genes is shown for both \>1.0-fold and ≥2.0-fold thresholds. The repressed genes are also shown for \<1.0- and \<0.5-fold thresholds.

^b^The total number of transcripts significantly changed (*p* ≤ 0.05) by proteasome inhibition.

^c^The number of ATF5-dependent transcripts that were significantly changed by proteasome inhibition.

^d^Numbers in parentheses are the percentage of CHOP-dependent genes compared with the total gene expression changed in response to MG132 treatment.

ATF5 was required for full mRNA induction of several known proapoptotic genes, including *NOXA* (*PMAIP1*), *APAF1*, and *TXNIP* ([Figure 7A](#F7){ref-type="fig"}). TXNIP is an example of the ATF5-specific genes reported to be involved in inflammation. ATF5 was recently reported to facilitate increased expression of thioredoxin-interacting protein (TXNIP) during ER stress, and knockdown of TXNIP was found to alleviate inflammation and subsequent apoptosis in pancreatic beta cells ([@B17]; [@B24]). By comparison, induction of *GADD34* mRNA in response to MG132 was not significantly altered upon knockdown of *ATF5*, highlighting this gene as an example of a CHOP-specific gene that can facilitate apoptosis during chronic stress ([Figure 6C](#F6){ref-type="fig"}). NOXA is a BH3-only member of the BCL2 family previously shown to be important for activation of apoptosis in response to ER stress ([@B42]). We found that *NOXA* mRNA levels were increased in an ATF5- and CHOP-dependent manner in our microarray data sets ([Figure 6C](#F6){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Of importance, *NOXA* transcripts were diminished as judged by qPCR in both *ATF5*-KD1 and *ATF5*-KD2 cells lines treated with MG132 as compared with WT cells ([Figure 7A](#F7){ref-type="fig"}). These results suggest that ATF5 and CHOP are nodes in an ISR transcription factor network that participate in the cellular decision to invoke apoptosis during extended disruptions in protein homeostasis.

The ATF5 target gene *NOXA* is required for increased apoptosis in response to proteasome inhibition
----------------------------------------------------------------------------------------------------

To address the role of ATF5- and CHOP-target gene *NOXA* in the regulation of cell survival during proteasome inhibition, we used shRNA to knock down *NOXA* mRNA in MEF cells. *NOXA* knockdown was confirmed by qPCR, with substantial reductions in *NOXA* mRNA levels in both of the shRNA-expressing cell lines ([Figure 7B](#F7){ref-type="fig"}). The MEF cells depleted for *NOXA* expression were treated with MG132 for 24 h and found to significantly enhance cell viability, as judged by the MTT assay. The increase in cell viability was comparable to that determined for the *CHOP*^−/−^ cells, further supporting the idea that NOXA is an important target for the ISR ([Figure 7C](#F7){ref-type="fig"}). Knockdown of *TXNIP* by shRNA significantly lowered the induction of *TXNIP* mRNA in response to MG132 but did not alter survival of the MEF cells ([Figure 7, D and E](#F7){ref-type="fig"}). These results support a model in which ATF5 is an apoptotic transcriptional regulator downstream of CHOP that facilitates apoptosis by enhanced *NOXA* expression.

DISCUSSION
==========

This study characterized the mechanisms by which CHOP directs gene regulatory networks that determine cell fate. In response to proteasome inhibition, CHOP induces the expression of a collection of transcription regulators, including ATF5 ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, and Supplemental Table S1). Transcriptional expression of *ATF5* is suggested to be directly activated by CHOP and ATF4 ([Figure 3](#F3){ref-type="fig"}), coincident with preferential translation of *ATF5* in response to eIF2α∼P ([@B49]). Like CHOP, ATF5 functions to enhance apoptosis during perturbations in protein homeostasis ([Figure 5](#F5){ref-type="fig"}). Microarray analysis revealed that an ATF5-dependent gene, *NOXA*, is important for inducing cell death during proteasome inhibition ([Figures 6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}; [@B6]; [@B32]; [@B42]). This study indicates that CHOP and the ISR activate a network of transcriptional regulators featuring ATF5, which triggers apoptosis upon disturbances in protein homeostasis.

The ISR features a network of transcription factors with a feedforward loop that controls cell fate
---------------------------------------------------------------------------------------------------

This study describes three transcriptional factors in the ISR with a network of interactions featuring a feedforward loop ([Figure 8](#F8){ref-type="fig"}). Transcriptional expression of each transcription factor node---ATF4, CHOP, and ATF5---is increased during proteasome inhibition. ATF4 enhances *CHOP* and *ATF5* mRNA levels, whereas CHOP facilitates the induction of *ATF5* transcripts ([Figure 8](#F8){ref-type="fig"}). We do not fully understand the underlying processes by which the transcriptional expression of ATF4 is enhanced in the ISR, but eIF2α∼P is suggested to be a contributing factor ([@B19]). ATF4 and CHOP bind the CARE-2 site in the *ATF5* promoter, a finding that is also supported by a recent ChIP-Seq analysis of ATF4- and CHOP-binding sites in MEF cells during tunicamycin treatment ([@B8]). There was appreciable ATF4 and CHOP association at the CARE-2 in the absence of stress, suggesting that there can be some binding of these transcription factors at the *ATF5* promoter even when ATF4 and CHOP are not easily measured by immunoblot analysis. Indeed *ATF4*^−/−^ MEF cells are prone to oxidative stress ([@B11]), suggesting that even basal levels of ATF4 contribute to the health of cells. Binding of ATF4 and CHOP at the CARE-1 site in the *ATF5* promoter was modest, albeit detectable, with some additional binding upon MG132. This suggests that there can be some association of these transcription factors at the suboptimal CARE-1 site. An alternative explanation is that even with aggressive sonication in the ChIP analysis there is the potential of ATF4- and CHOP-precipitated DNA containing both sequences, which are separated by ∼500 base pairs.

![The ISR features a network of ATF4, CHOP, and ATF5 transcription factors in a feedforward loop that controls cell fate. Different stress conditions that disrupt protein homeostasis induce phosphorylation of eIF2, leading to enhanced expression of the bZIP transcription factors ATF4, CHOP, and ATF5 through increased translation, as indicated by the green arrows. ATF4 and CHOP bind the ATF5 promoter and serve to enhance the transcription of *ATF5*, and CHOP and ATF5, individually or in combination, induce the transcription of target genes (blue arrows). These target gene products affect feedback control, apoptosis, and inflammation, which together can determine cell fate. ATF4 may also serve as a direct contributor to the transcription of some of these target genes, as illustrated by the finding that ATF4, as well as CHOP, can directly bind to the *GADD34* promoter to promote transcription ([@B20]; [@B21]; [@B14]).](2477fig8){#F8}

Overexpression of *CHOP* in the *CHOP*^−/−^ cells led to elevated levels of *ATF5* mRNA even the absence of stress ([Figure 4C](#F4){ref-type="fig"}). This suggests that although ATF4 and CHOP bind directly to the *ATF5* promoter, CHOP may be sufficient for induced *ATF5* transcription, at least when *CHOP* is highly expressed. In this regard, regulation of *ATF5* transcription follows the pattern of dynamic binding of bZIP transcription factors, such as ATF4 and CHOP, which has been described for the promoters of other ISR target genes ([@B15]). Accompanying this transcriptional mode of regulation, *ATF4*, *CHOP*, and *ATF5* mRNAs are preferentially translated in response to eIF2α∼P ([Figure 8](#F8){ref-type="fig"}). Therefore with chronic disruptions of protein homeostasis there can be high levels of uninterrupted eIF2α∼P, which will amplify the levels of each transcription factor to a proposed threshold that switches the ISR to a terminal outcome. Heterodimerization with other bZIP transcription factors, posttranslational modifications, and subcellular localization can also contribute to the biological functions of ATF4, CHOP, and ATF5 ([@B46]; [@B44]; [@B5]; [@B18]).

The ISR network of transcription factors can induce the expression of three classes of target genes ([Figure 8](#F8){ref-type="fig"}). The first group is dependent on only the ATF5 transcription factor. Included among the ATF5-specific genes is *TXNIP*. Elevated levels of TXNIP during certain ER stress conditions can dampen the function of thioredoxins, increasing reactive oxygen species and enhancing caspase-1 cleavage and interleukin-1b production through TXNIP binding to the NLRP3 inflammasome, which together can trigger caspase-3 cleavage and death of pancreatic β-cells ([@B17]; [@B24]). ATF5 levels are sharply reduced in the absence of *CHOP*, suggesting that the promoters of genes targeted solely by ATF5 have a higher affinity for this transcription factor. In addition, shRNA-directed knockdown of *TXNIP* did not alter survival of MEF cells treated with MG132 ([Figure 7, D and E](#F7){ref-type="fig"}), suggesting that differences in cell types and stress conditions can alter the signaling pathways regulating cell survival. The second group includes CHOP-specific genes, exemplified by *GADD34*, which functions to dephosphorylate eIF2α∼P in feedback control of the ISR ([Figure 8](#F8){ref-type="fig"}). CHOP induction of *GADD34* expression is suggested to lower cell survival during chronic stress, as premature resumption of protein synthesis can lead to further protein misfolding and aggregation ([@B21]). The third group features genes requiring both CHOP and ATF5 for full expression ([Figure 8](#F8){ref-type="fig"}). This codependence may be the consequence of CHOP facilitating elevated expression of ATF5 protein in response to proteasome inhibition, aiding the binding of this transcription factor to the promoters of targeted genes. Alternatively, CHOP and ATF5 could activate gene expression by jointly associating at target promoters. Included among this third group is *NOXA*, which can induce apoptosis during stresses, such as proteasome inhibition ([@B6]; [@B32]; [@B42]). NOXA can bind and inhibit the BCL2 prosurvival family member MCL1, which facilitates permeabilization of the mitochondrial membrane, release of cytochrome C, and activation of the apoptosome complex and cleavage of caspases 3/9 ([@B29]; [@B47]). In addition, ATF5 facilitates expression of *APAF1* ([Figure 7](#F7){ref-type="fig"}), a key regulator of the apoptosome and apoptosis ([@B47]). Therefore CHOP and ATF5 control expression of multiple regulators of the intrinsic pathway of apoptosis in response to disruptions in protein homeostasis, with the overarching theme of induction of proapoptotic factors and repression of those facilitating survival.

Biological roles of ATF5
------------------------

*ATF5* mRNA was first identified in sensory neurons during embryonic development of the olfactory epithelium and vomeronasal organs, suggesting a role for ATF5 in olfactory neuron differentiation ([@B16]). Elevated *ATF5* mRNA has also been observed in gliobastomas and other selected tumors, and it was suggested that *ATF5* expression, which is diminished after neural development, can be restored upon cancer differentiation ([@B1]; [@B7]). These studies suggested that ATF5 is a significant contributor to proliferation of certain cancers. In other cell types, however, ATF5 was reported to reduce cell viability ([@B36]; [@B29]; [@B44]). In this way ATF5 may contribute to either cell survival or death, depending on the cell type, developmental stage, or stress condition. Our study indicates that CHOP and ATF5 can selectively target genes that adversely affect cells upon disruption of protein homeostasis. An important question for future studies is whether eIF2α∼P and the ISR also contribute to *ATF5* expression and its functions in cell fate during neural development and tumorigenesis.

MATERIALS AND METHODS
=====================

Cell culture and lentivirus shRNA knockdown
-------------------------------------------

WT and *CHOP^−/−^* MEF cells, described previously ([@B50]; [@B13]), were grown in DMEM (4.5 g/l glucose) and maintained at 37°C in an atmosphere of 5% CO~2~ and 95% air. Cells were cultured to ∼60--70% confluence so that the cells were still in a growth phase at the onset of the experiment. Mouse hepatoma cell line Hepa1-6 was also cultured in DMEM (4.5 g/l glucose). Cultured cells were treated with 1 μM MG132, 1 μM thapsigargin, 2 μM tunicamycin, 5 mM histidinol, or 20 μM sodium arsenite, as indicated. Specific experimental details regarding length of treatments are provided in the figure legends. Knockdown of *CHOP*, *ATF5*, *NOXA*, and *TXNIP* were carried out using a lentivirus delivery system featuring the Addgene third-generation series of plasmids and validated mission shRNA TRC clones (Sigma-Aldrich, St. Louis, MO) for generating lentivirus particles. The shRNAs used in the study are as follows: *ATF5*, TRCN0000075554, TRCN0000075555, TRCN0000075556, and TRCN0000075557; *CHOP*, TRCN0000305677, TRCN0000103707, and TRCN0000103706; *NOXA*, TRNC0000009708 and TRNC0000011816; *TXNIP*, TRNC0000181578. WT MEF cells or Hepa1-6 cells were transduced by replacing growth media with lentivirus-containing media. Transduced cells were then selected in the presence of puromycin, and the shRNA-expressing cells were expanded and used for experiments. To rescue expression in *CHOP*^−/−^ MEF cells, a *CHOP* cDNA, which was devoid of an upstream open reading frame that is important for translational control, was inserted by site-directed recombination into a single FRT site introduced in the *CHOP*-deficient cells.

Microarray analysis
-------------------

From WT and *CHOP^−/−^* MEF cells treated with 1 μM MG132 for 8 h or no stress, total RNA was extracted using TRIzol reagent following the manufacturer\'s instructions for adherent cells. RNA was purified using an RNeasy Kit (Qiagen, Valencia, CA). Array hybridization was carried out as previously described ([@B39]). Briefly, RNA was labeled using the Affymetrix protocol for 3′-IVT arrays (Affymetrix, Santa Clara, CA), and labeled cRNA was hybridized for 17 h to Affymetrix mouse 430 2.0 arrays. Signal values and detection calls were derived using the MAS5 algorithm in Affymetrix GeneChip Operating Software. Probe sets were eliminated from further analysis if an absent call was determined in \>50% of the samples in both the WT treated/untreated. These filtered data were imported into Partek Genomics Suite (Partek, St. Louis, MO), and hierarchical clustering and principal components analysis were used to detect any outlier arrays; none were found. Drug treatment significance was determined by *t* test, and genes were considered significantly changed if the *p* \< 0.05 in the WT samples. CHOP dependence was further defined from within this set of genes with *p* ≤ 0.05 between the WT and *CHOP^−/−^* cells treated with 1 μM MG132 for 8 h or no stress, and the fold change of the drug-treated WT *CHOP^−/−^* samples was \>1.0. Alternatively, RNA was purified from WT and *ATF5*-KD2 cells treated with 1 μM MG132 for 8 h or no stress. Total RNA was labeled using the Ambion WT Expression kit (Life Technologies, Carlsbad, CA), followed by the Affymetrix GeneChip WT Terminal labeling kit and hybridized to an Affymetrix Mouse 1.0 ST array. CEL files were imported into Partek Genomics Suite. RMA signals were generated for the core probe sets using the RMA background correction, quantile normalization, and summarization by median polish. Summarized signals for each probe set were log 2 transformed. Venn diagrams were created with the help of an online Venn diagram program (Venny) available at the following link: [bioinfogp.cnb.csic.es/tools/venny/](http://bioinfogp.cnb.csic.es/tools/venny/). CHOP- and ATF5-dependent gene expression was also analyzed using Ingenuity Pathway Analysis software package (Ingenuity Systems, Redwood City, CA). Microarray data are deposited in Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)) under the series number GSE43716. The following link was created to allow review of microarray data: [www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xfyxlqseyyqkmtm&acc=GSE43716](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xfyxlqseyyqkmtm&acc=GSE43716).

Immunoblot blot analyses
------------------------

Cellular lysates were prepared from cultured cells using RIPA-buffered solution containing 50 mM Tris-HCl (pH 7.9), 150 mM sodium chloride, 1% Nonidet P-40, 0.1% SDS, 100 mM sodium fluoride, 17.5 mM β-glycerophosphate, 0.5% sodium deoxycholate, and 10% glycerol supplemented with EDTA-free protease inhibitor cocktail tablet (Roche, Indianapolis, IN) and then separated by electrophoresis in SDS--polyacrylamide gels. Antibodies for eIF2α∼P (Ser-51) (9721, 1:500 dilution), cleaved caspase-3 (9661, 1:1000 dilution), and PARP (9542, 1:1000 dilution) were purchased from Cell Signaling Technology (Beverly, MA). Monoclonal antibody that recognizes total eIF2α (dilution 1:500) was provided by Scot Kimball (College of Medicine, Pennsylvania State University, Hershey, PA). CHOP/GADD153 (sc-7351, 1:500 dilution), and ATF3 (sc-1888, 1:500 dilution) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Actin antibody (A5441, 1:1000 dilution) was from Sigma-Aldrich. Secondary antibodies were purchased from Bio-Rad (Hercules, CA). ATF4 (1:500 dilution) and ATF5 (1:300 dilution) antibodies were prepared and affinity purified as previously described ([@B49]). Autoradiography or the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE) was used in conjunction with the enhanced chemiluminescence method for antibody detection as described ([@B38]). Densitometric measurements (integrated density) were taken in Photoshop (Adobe, San Diego, CA) using a scanned image \>600 dpi that was inverted for histogram analyses. Background measurements were also recorded and subtracted from final measurements.

Reverse transcription and real-time PCR
---------------------------------------

Total RNA was extracted from MEF cells using TRIzol reagent (Life Technologies, Grand Island, NY) following the manufacturer\'s instructions for adherent cells. Levels of the indicated mRNAs were determined by qPCR. Reverse transcription was carried out using 1 μg each of the RNA preparations and the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the manufacturer\'s instructions. Primers for SYBR Green detection of cDNAs are listed in Supplemental Table S2. Amplification and detection were performed on the LightCycler 480 (Roche) or the Realplex^2^ Master Cycler (Eppendorf, Hauppauge, NY). All measurements were recorded in biological and technical triplicates and normalized to β-actin mRNA. Results were obtained by the comparative *Ct* method and are expressed as fold change with respect to the untreated control.

Cell survival assays
--------------------

The CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI) was used for measuring cell survival. This assay was performed in a 96-well plate format and read on a 96-well plate reader at a wavelength of 570 nm. Initially, 5000 cells were plated in 50 μl of DMEM supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 μg/ml). After overnight incubation and cells adhered to the bottom of the wells, a final concentration of 1 μM MG132, or media control, was added to each well. Cells were incubated in the presence of the MG132 for 1, 3, 6, 12, or 18 h or no treatment. At the indicated times, the medium containing MG132 was removed by gentle aspiration with a 0.5- to 10-μl pipette tip, and cells were then washed with warm media and then cultured in media without stress for a total 24 h from the time of the onset of treatment with MG132. For example, the cells treated with MG312 for 1 h were washed and then cultured in the absence of this stress agent for 23 h. After 24 h, 15 μl of MTT dye solution was added to a final volume of 115 μl and then incubated with the cells for 4 h, followed by the addition of 100 μl of solubilization solution, as described by the manufacturer\'s protocol. The absorbance of the solution was then measured at 570 nm using a Spectra Max 340 96-well plate reader from Molecular Devices (Sunnyvale, CA).

Cell survival was also measured by fluorescence-activated cell sorting (FACS) using fluorescein isothiocyanate (FITC)--annexin V (556419; BD Biosciences, San Diego, CA) and propidium iodide (PI; BD Biosciences) following the manufacturer\'s instructions. Before treatment, cells were washed with fresh, warm media and new media containing MG132 or no stress agent was added. After 24 h of drug exposure, medium was removed and transferred to a 50-ml conical tube, and cells that remained attached to the plate were trypsinized and transferred to the 50-ml conical tube. Cells were then collected by low-speed centrifugation at 1000 rpm and washed with PBS. Cells were then transferred to a microcentrifuge tube and stained with the addition of 5 μl annexin V dye and 10 μl PI.

ChIP analysis
-------------

ChIP assays were performed as described (Chen *et al.*, 2004) with the following minor modifications. About (5--10) × 10^6^ MEF were used per treatment. Cells were cultured in DMEM supplemented with 1× nonessential amino acids, 2 mM glutamine, 100 mg/ml streptomycin sulfate, 100 U/ml penicillin G, 0.25 mg/ml amphotericin B, 10% (vol/vol) fetal bovine serum, and 1 μM 2-mercaptoethanol. Between 12 and 16 h before initiation of stress treatment, cells were given fresh medium and serum to ensure that no nutrient stress took place before the start of experimental incubations. Cells were replenished with the medium containing 2 μM tunicamycin, 1 μM thapsigargin, or 1 μM MG132 for 12 h. To fragment the chromatin, isolated nuclei were resuspended in 1 ml of lysis buffer and sonicated twice with the Fisher model 100 sonicator with power level at 15 W. Antibodies used are as follows: rabbit anti-ATF4 polyclonal; rabbit anti-GADD153 (CHOP) polyclonal antibody (Santa Cruz Biotechnology), and normal rabbit IgG (Santa Cruz Biotechnology). DNA enrichment was analyzed with real time qPCR with a DNA Engine Opticon 3 system (Bio-Rad, Hercules, CA) and detection with SYBR Green. The reaction mixtures with 2 μl of purified DNA, 10 μl of SYBR Green master mixture, and 5 pmol each of forward and reverse primers in a total volume of 20 μl were incubated at 95°C for 15 min, followed by amplification at 95°C for 15 s and 60°C for 60 s for 35 cycles. The primers used are listed in Supplemental Table S2. All experiments were performed in triplicate. Results are described as the ratio to a portion of total input DNA.
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